Zogenix, Inc. (ZGNX)

Check out top investors' recommendation for ZGNX
Last closing price (Jan 01 4:00 EDT):
0.00 (0.00%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
N/A ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
N/A
 ? 
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
N/A
 ? 
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
Description:
Zogenix, Inc., a pharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system disorders and pain. Its commercial product includes Sumavel DosePro (sumatriptan injection), a delivery system that offers needle-free subcutaneous administration of sumatriptan for the acute treatment of migraine and cluster headache. The company’s lead product candidate, Zohydro, a single-entity extended-release hydrocodone, which has completed Phase III clinical trials for the treatment of moderate to severe chronic pain requiring around-the-clock opioid therapy. It is also developing Relday, an injectable formulation of risperidone, which is in a Phase I clinical trial to treat the symptoms of schizophrenia and bipolar disorder in adults and teenagers with 13 years of age and older. Zogenix, Inc. markets and sells its Sumavel DosePro to wholesale pharmaceutical distributors and retail pharmacies in the United States. It has a licensing and distribution agreement with Desitin Arzneimittel GmbH to develop and commercialize DosePro in the European Union, Norway, Switzerland, and Turkey. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered in San Diego, California.
Sector:
Analyst
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
Return
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
Geoff Porges High Peaks Buy   Oct 05, '18     93.00  Oct 05, '19  N/A 
Annabel Samimy Stifel Nicolaus & Company, Inc. Buy   Aug 15, '18     69.00  Aug 15, '19  N/A 
Jason Butler JMP Securities Buy   Nov 27, '17     56.00  Nov 27, '18  N/A 
Tim Lugo William Blair & Company, L.L.C. Buy   Sep 29, '17       Sep 29, '18  N/A 
Annabel Samimy Stifel Nicolaus & Company, Inc. Buy   Sep 21, '17     26.00  Sep 21, '18  N/A 
Annabel Samimy Stifel Nicolaus & Company, Inc. Buy   Jun 26, '17     26.00  Jun 26, '18  N/A 
Michael Schmidt Leerink Swann Llc Buy   Oct 04, '16     17.00  Oct 04, '17  N/A 
Akiva Felt Oppenheimer & Co. Buy   Oct 21, '15   11.53  23.00  Oct 21, '16  -21.08% 
Akiva Felt Oppenheimer & Co. Buy   Aug 11, '15   18.94  23.00  Aug 11, '16  -51.69% 
Charles Graham Unaffiliated Buy   May 29, '15   13.60  1.95  Aug 29, '15  35.37% 
Jorge Aura Unaffiliated Buy   Nov 05, '14   11.20  3.00  Nov 05, '15  5.18% 
Akiva Felt Oppenheimer & Co. Buy   Oct 02, '14   10.00    Oct 02, '15  29.70% 
Akiva Felt Oppenheimer & Co. Buy   Aug 06, '14   10.80  2.50  Aug 06, '15  85.19% 
Tim Lugo William Blair & Company, L.L.C. Buy   Jul 02, '14   18.88    Jul 02, '15  -26.06% 
Annabel Samimy Stifel Nicolaus & Company, Inc. Buy   Apr 25, '14   2.71    Apr 25, '15  -43.17% 
Charles Graham Unaffiliated Buy   Dec 06, '13   3.25  6.50  Dec 06, '14  -63.38% 
Christopher Holterhoff Oppenheimer & Co. Buy   Nov 14, '13   2.86  5.00  Nov 14, '14  -56.29% 
Akiva Felt Oppenheimer & Co. Buy   Nov 14, '13   2.86    Nov 14, '14  -56.29% 
Annabel Samimy Stifel Nicolaus & Company, Inc. Buy   Oct 29, '13   2.98  5.00  Oct 29, '14  -55.37% 
Christopher Holterhoff Oppenheimer & Co. Buy   Aug 08, '12   2.07  3.00  Aug 08, '13  44.93% 
< previous12